Jun Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jun Jiang has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Rui Zhang
State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Air Force Medical University, Xi’an, China
22 shared publications - Weihong Wen
School of Life Sciences and Technology Northwestern Polytechnical University Xi'an China
22 shared publications - Weijun Qin
Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China
22 shared publications - Donghui Han
Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China
20 shared publications - Changhong Shi
Division of Cancer Biology, Laboratory Animal Center, Air Force Medical University, Xi’an, China
19 shared publications - Chao Xu
Department of Urology, Xijing Hospital, Air Force Medical University, Xi’an, China
19 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Wiley in Advanced Science
- Vol. 13 (48) , e75977
Cholesterol‐Mediated Metabolic‐mechanotransductive Crosstalk Orchestrates Castration Resistance in Prostate Cancer
Biophysical microenvironment fuels therapeutic resistance, yet the contribution of matrix stiffness to castration‐resistant prostate cancer (CRPC) remains poorly understood. In this study, we established a metabolic‐mechanotransductive crosstalk wherein cholesterol‐driven stromal reprogramming amplifies CRPC progression. Mechanistically, full androgen deprivation (FAD) induces cholesterol metabolic rewiring in prostate cancer (PCa) cells that orchestrates the CH25H‐dependent phenotype transformation of cancer‐associated fibroblast (CAF) into myofibroblastic CAF (myCAF). In turn, the resulting matrix stiffness induces unfolded protein response (UPR) and potentiates IRE1α kinase activity for Xbp1 splicing, while concurrently activating the integrin αVβ3/FAK/STAT3 axis to transcriptionally replenish Xbp1 substrate in PCa cells. This mechanosensitive adaptation thereby confers PCa with resistance to apoptosis induced by FAD. Consequently, pharmacological disruption of this metabolic‐mechanotransductive axis by targeting cholesterol metabolism or blockade of IRE1α‐XBP1s signaling significantly suppress tumor growth, representing a promising therapeutic strategy for CRPC progression.
- 4 June 2026
- Published by Wiley in Advanced Science
- Vol. 13 (48) , e75977
Open AccessCholesterol‐Mediated Metabolic‐mechanotransductive Crosstalk Orchestrates Castration Resistance in Prostate Cancer
Biophysical microenvironment fuels therapeutic resistance, yet the contribution of matrix stiffness to castration‐resistant prostate cancer (CRPC) remains poorly understood. In this study, we established a metabolic‐mechanotransductive crosstalk wherein cholesterol‐driven stromal reprogramming amplifies CRPC progression. Mechanistically, full androgen deprivation (FAD) induces cholesterol metabolic rewiring in prostate cancer (PCa) cells that orchestrates the CH25H‐dependent phenotype transformation of cancer‐associated fibroblast (CAF) into myofibroblastic CAF (myCAF). In turn, the resulting matrix stiffness induces unfolded protein response (UPR) and potentiates IRE1α kinase activity for Xbp1 splicing, while concurrently activating the integrin αVβ3/FAK/STAT3 axis to transcriptionally replenish Xbp1 substrate in PCa cells. This mechanosensitive adaptation thereby confers PCa with resistance to apoptosis induced by FAD. Consequently, pharmacological disruption of this metabolic‐mechanotransductive axis by targeting cholesterol metabolism or blockade of IRE1α‐XBP1s signaling significantly suppress tumor growth, representing a promising therapeutic strategy for CRPC progression.
- Open Access
- 6 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
CD248 acts as a mechanosensory switch in fibroblast subsets to establish distinct pathological niches in renal fibrosis
Although the heterogeneity and plasticity of fibroblasts are recognized hallmarks of tissue fibrosis, their specific contributions to renal fibrosis progression and the therapeutic validity of targeting key effector subsets remain key unanswered questions. Here, we revealed that diverse, functionally exclusive fibroblast subpopulations actively shape their local microenvironment. Pro-inflammatory fibroblasts (i-Fibs) construct immune-active areas, while pro-fibrotic fibroblasts (ECM-Fibs) generate fibrogenic zones. These two distinct microenvironments form a spatial mosaic, occupying mutually exclusive territories within the kidney tissue. We identified mechanotransduction as a signal governing the switch from i-Fibs to the pathogenic ECM-Fib phenotype. Through unbiased bioinformatics and genetic tools, we pinpointed CD248 as a specific cell-surface protein on this matrix-producing subset. Mechanistically, CD248, via its C-type lectin-like domain, senses the disordered matrix, promoting focal adhesion assembly and YAP nuclear translocation through an IQGAP1/ARF6-GTP-dependent axis, leading to a sustained feedback loop between aberrant matrix and myofibroblasts activation. A monoclonal antibody targeting CD248, IgG78, effectively interrupted this feedback loop, mitigating fibrogenesis both in vitro and in vivo in male mice. Collectively, this study established that fibroblast heterogeneity drives pathological niche specification in the fibrotic kidney and validated CD248 as a promising therapeutic target to counteract tissue fibrosis by disrupting aberrant mechanosignaling.
- 6 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCD248 acts as a mechanosensory switch in fibroblast subsets to establish distinct pathological niches in renal fibrosis
Although the heterogeneity and plasticity of fibroblasts are recognized hallmarks of tissue fibrosis, their specific contributions to renal fibrosis progression and the therapeutic validity of targeting key effector subsets remain key unanswered questions. Here, we revealed that diverse, functionally exclusive fibroblast subpopulations actively shape their local microenvironment. Pro-inflammatory fibroblasts (i-Fibs) construct immune-active areas, while pro-fibrotic fibroblasts (ECM-Fibs) generate fibrogenic zones. These two distinct microenvironments form a spatial mosaic, occupying mutually exclusive territories within the kidney tissue. We identified mechanotransduction as a signal governing the switch from i-Fibs to the pathogenic ECM-Fib phenotype. Through unbiased bioinformatics and genetic tools, we pinpointed CD248 as a specific cell-surface protein on this matrix-producing subset. Mechanistically, CD248, via its C-type lectin-like domain, senses the disordered matrix, promoting focal adhesion assembly and YAP nuclear translocation through an IQGAP1/ARF6-GTP-dependent axis, leading to a sustained feedback loop between aberrant matrix and myofibroblasts activation. A monoclonal antibody targeting CD248, IgG78, effectively interrupted this feedback loop, mitigating fibrogenesis both in vitro and in vivo in male mice. Collectively, this study established that fibroblast heterogeneity drives pathological niche specification in the fibrotic kidney and validated CD248 as a promising therapeutic target to counteract tissue fibrosis by disrupting aberrant mechanosignaling.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Table S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Table S3 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Expression of LHX2 in NEPC and SCLC
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Expression of LHX2 in NEPC and SCLC
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
LHX2 promotes DNMT1 expression
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
LHX2 promotes DNMT1 expression
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
LHX2 promotes cancer cell growth and sensitives cells to enzalutamide in vitro
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
LHX2 promotes cancer cell growth and sensitives cells to enzalutamide in vitro
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
AR activation inhibits but not transcriptionally regulates LHX2 expression
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
AR activation inhibits but not transcriptionally regulates LHX2 expression
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Table S1 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Table S1 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Table S4 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Table S4 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Primer sequences of the reporter constructs
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
Primer sequences of the reporter constructs